Press Announcements > FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

Press Announcements > FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic





FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic

The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Because of the risk of serious adverse outcomes resulting from sedation and dissociation caused by Spravato administration, and the potential for abuse and misuse of the drug, it is only available through a ...